Why did GAAP EPS rise while non-GAAP EPS was flat?

GAAP diluted EPS increased to $1.56 from $1.29 mainly because of net unrealized gains on equity securities versus losses a year earlier. Non-GAAP EPS excludes these fair value swings and most acquisition-related items, and was flat at $2.01 as higher product sales were offset by higher R&D spending. The underlying operating trend is better captured by the non-GAAP figure.

Is the guidance raise meaningful given the Veklury reduction?

Yes, in substance. Veklury guidance was cut by about $400 million to $1.0 billion, yet total product sales guidance was still raised slightly, implying stronger performance in the core portfolio. Non-GAAP diluted EPS guidance rose by $0.25 at the midpoint, showing that the core business is outperforming expectations even after the COVID-related decline.

What is the outlook for Yeztugo and the HIV franchise?

The FDA approved Yeztugo (lenacapavir) as the first twice-yearly HIV PrEP option in the U.S., which is a key growth driver for the long term. Near-term revenue contribution is not separately quantified in the filing. The FDA also placed a clinical hold on the GS-1720 and GS-4182 HIV treatment trials, which could delay the development of next-generation treatments and is a risk to watch.

How strong is Gilead's cash position and capital return capacity?

Cash and marketable securities declined to $7.1 billion from $10.0 billion at year-end 2024, largely due to the $1.3 billion transition tax payment and shareholder returns. Gilead still generated $2.6 billion in operating cash flow for the first half and maintained its dividend. The new $6.0 billion repurchase authorization signals confidence, though its pace will depend on cash generation and capital deployment priorities.

Does the DOJ settlement affect future results?

The DOJ settlement resolves a legacy compliance matter and was already accrued in 2024 and reported in SG&A, so it should not create a new charge this quarter. Investors should still note the matter's existence in assessing compliance risk, though the filing does not indicate a material ongoing impact.

GILD 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed August 7, 2025. Cited figures are marked; the original filing is the authoritative source.

Gilead Sciences reported second-quarter 2025 results on August 7, 2025, with total revenue up 2% to $7.1 billion^a and product sales excluding Veklury up 4% to $6.9 billion, led by HIV (up 7% to $5.1 billion, with Biktarvy up 9% and Descovy up 35%).

Trodelvy grew 14% and Livdelzi contributed to growth, while Liver Disease (down 4%), Veklury (down 44%), and Cell Therapy (down 7%) were weaker. GAAP diluted EPS rose to $1.56^b from $1.29, but this was flattered by $142 million of gains on equity securities; the $190 million IPR&D impairment (MYR acquisition assets) weighed on GAAP results. Non-GAAP diluted EPS was flat at $2.01.

Operating cash flow was $827 million^c after a final $1.3 billion transition tax payment, and free cash flow was $720 million. Management raised full-year guidance: product sales now $28.3-28.7 billion (up from $28.2-28.6 billion), non-GAAP diluted EPS now $7.95-8.25 (up from $7.70-8.10), and GAAP diluted EPS now $5.85-6.15. Veklury guidance was cut to about $1.0 billion from $1.4 billion, so the raise reflects growth in the core portfolio.

Key strategic developments include FDA approval of Yeztugo (lenacapavir) as the first twice-yearly HIV PrEP option, positive Phase 3 ASCENT-03 data for Trodelvy in first-line mTNBC, and an FDA clinical hold on the GS-1720 and GS-4182 HIV treatment trials. Capital allocation remained shareholder-friendly. Gilead paid $994 million^d in dividends and repurchased $527 million of stock in the quarter, declared a $0.79 quarterly dividend, and authorized a new $6.0 billion buyback.

Cash and marketable securities fell to $7.1 billion from $10.0 billion at year-end 2024, reflecting the transition tax payment and capital returns. The filing also disclosed a final settlement with the U.S. Department of Justice on a legacy compliance matter, which had been accrued in 2024.

02—Key points

Key Highlights

Total revenue rose 2% to $7.1 billion; product sales excluding Veklury grew 4% to $6.9 billion, driven by HIV, Livdelzi, and Trodelvy.
HIV sales increased 7% to $5.1 billion, with Biktarvy up 9% to $3.5 billion and Descovy up 35% to $653 million.
Non-GAAP diluted EPS was flat at $2.01, while GAAP diluted EPS rose to $1.56 from $1.29, helped by $142 million in equity securities gains.
Full-year guidance raised: product sales to $28.3-28.7 billion and non-GAAP diluted EPS to $7.95-8.25, partly offset by a Veklury cut to about $1.0 billion from $1.4 billion.
A $190 million IPR&D impairment related to the MYR acquisition weighed on GAAP results.
Operating cash flow was $827 million after a $1.3 billion final transition tax payment; free cash flow was $720 million.
Board authorized a new $6.0 billion share repurchase program and declared a $0.79 quarterly dividend; the quarter included $994 million in dividends and $527 million in buybacks.

03—Questions

Frequently Asked Questions

Why did GAAP EPS rise while non-GAAP EPS was flat?
GAAP diluted EPS increased to $1.56 from $1.29 mainly because of net unrealized gains on equity securities versus losses a year earlier. Non-GAAP EPS excludes these fair value swings and most acquisition-related items, and was flat at $2.01 as higher product sales were offset by higher R&D spending. The underlying operating trend is better captured by the non-GAAP figure.
Is the guidance raise meaningful given the Veklury reduction?
Yes, in substance. Veklury guidance was cut by about $400 million to $1.0 billion, yet total product sales guidance was still raised slightly, implying stronger performance in the core portfolio. Non-GAAP diluted EPS guidance rose by $0.25 at the midpoint, showing that the core business is outperforming expectations even after the COVID-related decline.
What is the outlook for Yeztugo and the HIV franchise?
The FDA approved Yeztugo (lenacapavir) as the first twice-yearly HIV PrEP option in the U.S., which is a key growth driver for the long term. Near-term revenue contribution is not separately quantified in the filing. The FDA also placed a clinical hold on the GS-1720 and GS-4182 HIV treatment trials, which could delay the development of next-generation treatments and is a risk to watch.
How strong is Gilead's cash position and capital return capacity?
Cash and marketable securities declined to $7.1 billion from $10.0 billion at year-end 2024, largely due to the $1.3 billion transition tax payment and shareholder returns. Gilead still generated $2.6 billion in operating cash flow for the first half and maintained its dividend. The new $6.0 billion repurchase authorization signals confidence, though its pace will depend on cash generation and capital deployment priorities.
Does the DOJ settlement affect future results?
The DOJ settlement resolves a legacy compliance matter and was already accrued in 2024 and reported in SG&A, so it should not create a new charge this quarter. Investors should still note the matter's existence in assessing compliance risk, though the filing does not indicate a material ongoing impact.

04—Continue

← View all 8-K filings